Theorem Clinical Research

EntreMed

EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »


EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »


EntreMed initiates phase II trial in advanced/metastatic soft tissue sarcoma

Friday, January 25, 2013 01:11 PM

EntreMed, a clinical-stage pharmaceutical company, has initiated a single-center phase II study of oral ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.

More... »

EntreMed appoints Ren as interim CEO

Wednesday, April 4, 2012 12:43 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Ken K. Ren as interim CEO, effective April 2, 2012.

More... »

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs